In this study, we identified co-expressed biomarkers for degenerative CNS diseases and GBM: RELN and GSTO2. Validated experimental results indicated that, in GBM patient samples, the expression levels of RELN and GSTO2 were significantly reduced compared to healthy controls. The gene discussed is GSTO2; the disease is glioblastoma.